Should You Buy the Dip in Tilray?

: TLRY | Tilray Brands Inc. Cl 2 News, Ratings, and Charts

TLRY – Although Tilray’s (TLRY) shares spiked last year on a booming cannabis market, it declined this month on investors’ anxiety surrounding the company’s recent merger plans and poor earnings growth in its last reported quarter. In addition, the company’s pricey valuation could make it more difficult for its stock to gain in the near term. Let’s take a closer look.

Shares of the Canadian pharmaceutical and cannabis company Tilray, Inc. (TLRY) tanked this month after rallying significantly on hopes that Congressional Democrats would soon pursue federal decriminalization of marijuana and on the enthusiasm of casual traders uniting on Reddit. With investors’ fading optimism and consequent profit-taking, the stock has lost 57.6% since February 10.

Investors’ concerns surrounding TLRY’s impending merger with Aphria, Inc. (APHA) and possible headwinds for the Canadian cannabis market and/or the U.S. hemp foods market could pose new challenges for the stock.

While the merger with APHA will create a powerhouse in the cannabis industry, the potential for it to succeed will depend on many factors. And it could take some time before the combined entity generates meaningful  profits. Thus, we believe the stock does not have the potential to rebound in the near term.

Here is what we think could influence the performance of the stock in the near term:

A Big Merger Could Present Challenges

Last December, APHA and TLRY entered  an  agreement to merge their businesses and create the world’s largest global cannabis company based on pro forma revenue. However, a merger of this scale is complicated, involving, for example, the estimation cost synergies, operational inefficiencies and high merger cost. Moreover, the companies’ claims that the marriage will create the world’s top cannabis company could be a difficult  support, with TLRY generating loss in the last reported quarter.

Lingering Obstacles in The Cannabis Industry

While the cannabis industry has boomed amid the coronavirus pandemic, with more states legalizing its use, the legalization question remains very much a local one, with policies set by individual counties and cities. Cannabis operations are still largely prohibited outside of corporate structures. In fact, federal cannabis taxation could also be crippling to many businesses. Also,  the future demand for cannabis is expected to be lower than during the pandemic lockdown period as people begin returning to outdoor activities and recreation. These  factors could dent TLRY’s operations and significantly  lower its growth potential  in the near term.

Unimpressive Fourth-Quarter Results

TLRY’s hemp revenue has declined 18% year-over-year to $15.33 million in the fourth quarter ended December 31, 2020. The company generated a net loss of $2.95 million and an operating loss of $21.28 million. Its loss per share was  $0.02 for this period. TLRY’s interest expenses increased 4.5% from the year-ago value to $9.07 million.

Stretched Valuation

In terms of forward ev/sales , TLRY is currently trading at 27.90x, which 203.9% higher than the industry average 9.18x. Its trailing-12-month price/sales of 22.32x is 145.7% higher than the industry average 9.08x. Also, its trailing-12-month price-to-book of 24.72x is 368.4% higher than the industry average  5.28x.

Consensus Price Target Indicates Potential Downside

Currently trading at $27.10, Wall Street analysts expect TLRY’s  stock to hit  $10.97 in the near term, which indicates a potential downside of 60%.

POWR Ratings Indicate Poor Prospects

TLRY has an overall rating of D, which translates to Sell in our POWR Ratings system. The POWR Ratings are calculated by considering 118 different factors with the weighting of each optimized to improve overall performance.

Our proprietary rating system also evaluates each stock based on eight different categories. TLRY has a Value Grade of F. This is in sync with the stock’s stretched valuation.

TLRY also has a B grade for Momentum, which is consistent with the stock’s 99.1% gains over the past year. It has a C grade for Growth, given its poor revenue and earnings growth prospects.

The stock is currently ranked #221 of 238 stocks in the F-rated Medical -Pharmaceuticals industry. In addition to the grades I’ve highlighted, you can check out TLRY’s POWR Ratings for Stability, Sentiment and Quality here.

If you’re looking for better stocks in the Medical-Pharmaceuticals industry, with an Overall POWR Rating of A or B, you can access them here.

Bottom Line

We think that TLRY’s recent price dip makes the stock  less compelling. Given its concerning merger plans, weak financials, sky-high valuation, and potential headwinds for the cannabis and hemp market, the stock could plunge further in the upcoming months.

Want More Great Investing Ideas?

“MUST OWN” Growth Stocks for 2021

How to Ride the 2021 Stock Market Bubble

7 Best ETFs for the NEXT Bull Market

5 WINNING Stocks Chart Patterns

 


TLRY shares were trading at $28.43 per share on Friday morning, up $1.33 (+4.91%). Year-to-date, TLRY has gained 244.19%, versus a 4.78% rise in the benchmark S&P 500 index during the same period.


About the Author: Imon Ghosh


Imon is an investment analyst and journalist with an enthusiasm for financial research and writing. She began her career at Kantar IMRB, a leading market research and consumer consulting organization. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
TLRYGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


:  |  News, Ratings, and Charts

Recession is Here...Watch Out Below!

More and more it looks like recession is here. This includes a dramatic decline for ISM Manufacturing discovered this morning. As you likely know, most economist call manufacturing the "canary in the coal mine" for the US economy as it often shows weakness before other areas. In fact, GDP Now from the Atlanta Fed reads it loud and clear with a negative revision for the US economy down to -2.1% for Q2. Ouch! We are going to discuss these new economic facts...what it means for the stock market outlook...and an interesting view on why the S&P 500 (SPY) does not decline in orderly fashion. All that and more is coming your way in this week's commentary…

:  |  News, Ratings, and Charts

4 Ideal Stocks to Add to Your Portfolio in July

While sluggish consumer spending data led to the stock market ending the last trading session of June in the red, a moderate inflation forecast is nurturing hopes over the economy to avoid a recession. Therefore, investors might consider buying quality stocks ARC Document Solutions (ARC), Core Molding Technologies (CMT), DLH Holdings (DLHC), and Friedman Industries (FRD) at their current low price levels to benefit from their big rebounds. Read more…

:  |  News, Ratings, and Charts

Stocks to Fall MUCH FURTHER this Bear Market Cycle

Spoiler alert...the bear market is not over. Unfortunately history shows that the S&P 500 (SPY) has much further to fall to squeeze out excess valuation. That is just a natural part of the bear market process that is properly explained in this timely market commentary. More importantly, this commentary provides a strategy on how to profit in the days and weeks ahead as the market finds its way to bottom. Read on below for more...

:  |  News, Ratings, and Charts

Wall Street Analysts Predict More Than 160% Upside in These Stocks

The high global inflation and hawkish federal reserve are leading to heightened volatility in the market. However, despite the market uncertainties, Wall Street analysts see a more than 160% upside potential in IonQ (IONQ) and Rigetti Computing (RGTI). Thus, these stocks could be ideal additions to your watchlist. Keep reading…

:  |  News, Ratings, and Charts

Stocks to Fall MUCH FURTHER this Bear Market Cycle

Spoiler alert...the bear market is not over. Unfortunately history shows that the S&P 500 (SPY) has much further to fall to squeeze out excess valuation. That is just a natural part of the bear market process that is properly explained in this timely market commentary. More importantly, this commentary provides a strategy on how to profit in the days and weeks ahead as the market finds its way to bottom. Read on below for more...

Read More Stories

More Tilray Brands Inc. Cl 2 (TLRY) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All TLRY News